Toremifene

Drug Profile

Toremifene

Alternative Names: Fareston; FC 1157; FC 1157a; NK 622; Toremifene citrate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orion
  • Developer GTx
  • Class Antineoplastics; Dimethylamines; Phenyl ethers; Small molecules; Stilbenes
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer
  • Discontinued Androgen deprivation therapy complications; Non-small cell lung cancer; Prostatic intraepithelial neoplasia; Renal cancer

Most Recent Events

  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2012 Toremifene is no longer licensed to GTx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top